The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
For sufferers residing with metastatic colorectal most cancers whose illness has progressed after commonplace chemotherapy, remedy choices may be restricted and outcomes...
New real-world proof means that remedy alternative might make a significant distinction for sufferers dwelling with metastatic castration-sensitive prostate most cancers (mCSPC),...
